Adaptation of the Golgi Apparatus in Cancer Cell Invasion and Metastasis

Sarah Bui1, Isabel Mejia2, Begoña Diaz2,3* and Yanzhuang Wang1,4*

1Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI, United States, 2Department of Internal Medicine, Division of Medical Hematology and Oncology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, United States, 3David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, United States, 4Department of Neurology, University of Michigan School of Medicine, Ann Arbor, MI, United States

The Golgi apparatus plays a central role in normal cell physiology by promoting cell survival, facilitating proliferation, and enabling cell-cell communication and migration. These roles are partially mediated by well-known Golgi functions, including post-translational modifications, lipid biosynthesis, intracellular trafficking, and protein secretion. In addition, accumulating evidence indicates that the Golgi plays a critical role in sensing and integrating external and internal cues to promote cellular homeostasis. Indeed, the unique structure of the mammalian Golgi can be fine-tuned to adapt different Golgi functions to specific cellular needs. This is particularly relevant in the context of cancer, where unrestrained proliferation and aberrant survival and migration increase the demands in Golgi functions, as well as the need for Golgi-dependent sensing and adaptation to intrinsic and extrinsic stressors. Here, we review and discuss current understanding of how the structure and function of the Golgi apparatus is influenced by oncogenic transformation, and how this adaptation may facilitate cancer cell invasion and metastasis.

Keywords: Golgi, cancer, dissemination, metastasis, oncogenic transformation, proliferation, signaling, tumorigenesis

1 INTRODUCTION

The Golgi apparatus is an essential eukaryotic cell organelle that mediates protein and lipid glycosylation, lipid biosynthesis, intracellular trafficking, and protein secretion. In mammalian cells, the Golgi apparatus also functions as a microtubule organizing center, an intracellular signaling platform, and a stress sensor (for excellent recent reviews see (Mayinger, 2011; Sasaki and Yoshida, 2015; Wu and Akhmanova, 2017)). All these functions are essential for cell proliferation, survival, migration, and cell-cell communication during normal physiology as well as during cancer progression. In cancer cells, the functions of membrane organelles, including the endoplasmic reticulum (ER), mitochondria and lysosomes, are adapted to support continuous proliferation and evasion from cell death. However, the adaptation of the Golgi apparatus in cancer cells has been less extensively studied.

The morphology of the Golgi apparatus is dynamic, and becomes profoundly altered during cell division, when the stacked Golgi structure completely disassembles and reforms in the daughter cells. During interphase, its complex architecture is linked to its function. For instance, glycosylation and cargo sorting are defective when Golgi is experimentally forced to disassemble in interphase (Xiang et al., 2013; Bekier et al., 2017). Furthermore, the Golgi in mammalian cells forms a ribbon in which several cisternae stacks link laterally. The Golgi ribbon appears to be important for the non-classical functions of the mammalian Golgi on intracellular signaling and stress sensing (Makhoul et al., 2018).
Here, we review and discuss our current knowledge on the morphological and functional adaptations of the Golgi apparatus during cancer invasion and metastasis. First, we will briefly introduce the different Golgi morphologies of cancer cells. In the following sections, we emphasize the role of the Golgi in each step of the metastatic cascade by presenting the most representative studies that convey its multifaceted participation in cancer progression. We highlight examples of Golgi-specific proteins regulating metastatic phenotypes and discuss how these conceptual advances in understanding Golgi in cancer can guide us in developing better diagnostic tools and therapeutic options in the future.

2 THE GOLGI MORPHOLOGY IN CANCER CELLS

The exact feature of Golgi in cancer cells remains debated; although it is clear that both the structure and function of this organelle is affected by the hallmarks of cancer, which in turn can also promote those fundamental traits of cancer by causing aberrant glycosylation, enhancing survival and proliferation, and increasing migration. Early studies described abnormal morphology as a common feature of the Golgi in cancer (Maldonado et al., 1966; Kellokumpu et al., 2002; Petrosyan, 2015). The Golgi in cancer cells often appears as constitutively disassembled in discrete units distributed throughout the cytoplasm. In some cancer cells, cisternal stacks are maintained, but they lack its characteristic ribbon organization (Figure 1). In other cases, the stacks themselves are disassembled, or even fragmented (Figure 1). Lastly, the Golgi morphology in some cancer cells is indistinguishable from non-cancerous cells (Figure 1). It remains unclear to what extent the alteration in Golgi morphology of cancer cells reflects a functional adaptation that actively contributes to malignancy or simply a bystander effect of cancer cell transformation. Recent studies suggest that dynamic regulation of Golgi morphology may indeed contribute to cancer malignancy.

2.1 Golgi Fragmentation in Cancer

Given the wide range of Golgi morphologies observed across cancer types, we will first briefly summarize the molecular changes regulating Golgi structure that generally coincide with cancer progression.

Golgi dispersal in cancer cells—Cancer cell lines across a wide variety of cancer types, including colon (Egea et al., 1993; Kellokumpu et al., 2002), breast (Sewell et al., 2006), gastric (He et al., 2010), and prostate cancer cells (Petrosyan et al., 2014; Nolfi et al., 2020), display fragmented Golgi. In tissue culture, the Golgi ribbon is intact in many cancer cell lines, but it undergoes morphological change upon the induction of epithelial-to-mesenchymal transition (EMT) or migration (Bisel et al., 2008b). Golgi fragmentation is often seen in various tumor tissue types from patients (Maldonado et al., 1966; Tani et al., 1975; Castejón, 1999; Kellokumpu et al., 2002; Sano et al., 2002; Zhang, 2021). Frozen tissue sections showed intact Golgi structure in normal colon epithelial cells, in contrast to small punctate Golgi structure found in cancerous colon epithelium.
were correlated with Rab25 overexpression and kinase activation (Ching et al., 2007; Weller et al., 2010; Capaci et al., 2012, 2017). Reports of fragmented Golgi in ovarian and breast cancer cells. However, a correlative link between aberrant kinase phosphorylation of Golgi structural proteins results in Golgi disassembly to better understand how the Golgi structure is affected in cancer pathogenesis.

2.2 Other Golgi Phenotypes in Cancer

Overexpression of Golgi matrix proteins such as GRASP55 and GRASP65 have been correlated with poor prognosis in some cancer patients, suggesting that they have important functions in tumor cells. However, it is unclear if the Golgi in these tumors with high expression of Golgi matrix proteins display compact Golgi phenotypes. GRASP55 was shown to be hypomethylated and hence overexpressed in invasive adenocarcinoma (Husni et al., 2019). GM130 expression is positively correlated with invasion and poor prognosis in lung and gastric tumors (Chang et al., 2012; Zhao et al., 2015). GOLM4 was shown to promote tumorigenesis in nasopharyngeal carcinoma through maintaining the organization of Golgi (Luo et al., 2021). Golgi compaction in cancers has been linked to EMT (Tan et al., 2017). Cancer EMT is considered now as a spectrum of hybrid or partial E/M states, rather than a two-state paradigm; therefore, it is reasonable to hypothesize that if Golgi morphology is correlated with epithelial and mesenchymal states, then Golgi architecture would span a range of structures in varying degrees of dispersal as well as compaction. Without complete fragmentation, the Golgi can be fenestrated (Tani et al., 1975). “honey-comb” patterned (Sano et al., 2002), or extended phenotype (Halberg et al., 2016) in different tumors. It is becoming more apparent, as more studies are investigating the role of Golgi in cancer, that this dynamic organelle is at the center of the many biological processes involved in metastasis.

3 THE MOLECULAR MECHANISM OF GOLGI ADAPTATION IN METASTASIS

3.1 The Metastatic Cascade

Metastasis is an extremely complex pathological process and understanding it is fundamental to achieve the elusive goal of finding curative treatments for advanced cancers. The metastatic cascade model (recently reviewed in Lambert et al., 2017) presents metastasis as a stepwise process (Figure 2) that starts...
when a subset of cancer cells residing in the primary tumor acquire invasive capacity. Acquisition of aberrant invasiveness enables cancer cells from solid tumors to travel through the surrounding tissues and reach the blood or lymphatic circulatory systems for metastatic dissemination. After entering the vessels by a process called intravasation, those cancer cells that survive in circulation and successfully leave the circulation (extravasation) at distant sites may subsequently form micrometastasis (metastatic colonization). When disseminated cancer cells proliferate to form macroscopic secondary tumors, the metastatic cascade is completed (Figure 2).

At each step of the metastatic cascade, cancer cell intrinsic factors, such as driver mutations in oncogenes and/or tumor suppressors, cooperate with cancer cell extrinsic factors, such as signals from the tumor microenvironment, to promote metastasis (Lambert et al., 2017). The tumor microenvironment is comprised of cellular and non-cellular components, and the crosstalk between these and the cancer cells not only promotes the growth of the primary tumor, but also its metastatic competency. The reciprocal interactions between cancer cells and the tumor microenvironment may be established through communication by either direct contact (cell-matrix or cell-cell), or by indirect contact (autocrine, juxtacrine and paracrine signaling). Activation of cell surface receptors by ligands is central to the above communication mechanisms and is often coupled with aberrant remodeling of the extracellular matrix during invasion and metastasis. Cell surface receptors, secreted and transmembrane ligands, matrix proteases and extracellular vesicles are all essential for the cross-talk between cancer cells and the tumor microenvironment, and, therefore, modulate one or more steps of the metastatic cascade.

Most of these molecules are processed and sorted in the Golgi apparatus, placing this organelle at a central position in the regulation of invasion and metastasis. Importantly, recent findings indicate that the central role of the Golgi apparatus in sustaining invasion and metastasis goes beyond its function in receptor and ligand post-translational modifications, lipid biosynthesis, intracellular trafficking, protein secretion, and formation of extracellular vesicles (Petrosyan, 2015). As mentioned earlier, the Golgi apparatus is also an intracellular signaling platform (Chiu et al., 2002) and a homeostasis sensor that detects and responds to stress (Zhang et al., 2018; Zhang et al., 2019; Ireland S. C. et al., 2020). These non-classical Golgi functions are currently the focus of active investigation during disease states and appear highly relevant during cancer invasion and metastasis.

3.2 Golgi Adaptation During Cancer Cell Invasion

3.2.1 Epithelial to Mesenchymal Transition

EMT and transcriptional regulation - Cell invasion into the tissues surrounding the primary cancer lesion is the first step of the metastatic cascade. In the case of solid tumors of epithelial origin, which represent the majority of human cancers, the acquisition of invasive capacity is associated with aberrant reactivation of the developmental process of epithelial to mesenchymal transition (EMT), recently reviewed in (Dongre and Weinberg, 2019). This process is characterized by the loss of cell-cell contact and the acquisition of cytoskeletal changes that facilitate cell motility (Figure 3). Expression of a set of specific transcription factors,
including SNAIL, TWIST, and ZEB families, drives the EMT program during development and cancer progression. Interestingly, PAQR3 a Golgi scaffolding protein (also named RKTG for Raf kinase trapping to the Golgi) is actively involved in the degradation of Twist1, a critical transcription factor required for the initiation of EMT and metastasis of tumor cells (Guo et al., 2016). Although well-studied instances of Golgi directly regulating EMT-associated transcription factors are not available, it is known that EMT during cancer progression is aberrantly activated by a variety of factors, including amino acid starvation—to which the Golgi is highly responsive. Once the invading cells reach their final destination, they often partially reverse their EMT phenotype. However, as mentioned earlier, EMT in cancer is not completely resolved and cancer cells often retain a mixture of mesenchymal and epithelial traits which confer these cells with the necessary plasticity to adapt to changing environments (Yang et al., 2020).

Pro-tumorigenic secretion during EMT—Interestingly, compaction of the Golgi apparatus has recently been discovered as part of the EMT program (Tan et al., 2017). Enhanced Golgi ribbon linking and stack formation through Golgi scaffolding protein PAQR11 (progestin and adipoQ receptor 11) enables Golgi compaction. Furthermore, p53 loss up-regulates the expression of PAQR11 and promotes a pro-tumorigenic secretory phenotype by recruiting ARF1 to Golgi membranes, which facilitates cargo-loading into vesicles destined for the extracellular space. In particular, the secretion of PLAU, a protease that prevents the induction of apoptosis in cells upon loss of attachment to the extracellular matrix (ECM) and neighboring cells during EMT, is dependent on PAQR11 (Tan et al., 2021).

Alteration of Golgi glycosylation enzymes during cancer invasion—During cancer progression, EMT contributes to malignancy, as dissolution of cell-cell junctions allows cancer cells to detach from the primary tumor, migrate, and survive in transit to secondary sites of metastasis. A typical example of cancer-related EMT is cadherin switching between E- and N-cadherins. Interestingly, E-cadherin trafficking to the plasma membrane is dependent on Golgin-97 (Lock et al., 2005), a tethering factor in the trans-Golgi network (TGN). Increased N-glycosylation of E-cadherin with bisecting GlcNAc structures by Golgi resident enzyme Gn-TIII (N-acetylglucosaminyltransferase III) promotes E-cadherin cell surface stability and function (Yoshimura et al., 1996; Pinho et al., 2012). During EMT, expression of GnT-III and its bisecting GlcNAc structures is reduced; while Gn-T-V and its 1,6 GlcNAc branching structures, which have been associated with enhanced malignancy and metastasis, are increased (Asada et al., 1997; Granovsky et al., 2000; Gu and Taniguchi, 2008; Gu et al., 2009). Remarkably, a recent study showed that methylation and demethylation of the promoter are involved in regulating the expression of GnT-III during EMT and MET, respectively. Knockdown of GalNAC-T3 (GALTNT3) can initiate EMT through aberrant E-cadherin glycosylation (Raghu et al., 2019).

RAS activation at the Golgi during EMT - Other oncogenes such as the Ras family, encoded by the KRAS, HRAS, and NRAS genes, are also integral molecular players in cancer cell invasion. Recent evidence supports the function of Ras oncoproteins in tumor cell acquisition of EMT features. Ras signaling through phosphoinositide 3-kinase (PI3-Kinase) and Raf Kinase Inhibitory Protein (RKIP) cooperatively regulate epithelial cell plasticity and fine tunes cancer cell motility (Schuierer et al., 2004; Tripathi and Garg, 2018). The Ras family are among the most frequently altered and some of the earliest described oncogenes in human malignancies. They play numerous functions not limited to supporting proliferative signaling, survival pathways, metabolic and immunologic functions; as well as regulating cell morphology, differentiation, cellular adhesion, cell invasion and migration. Ras proteins have been found on the plasma membrane, in the endoplasmic reticulum, endosomal network, mitochondria, and the Golgi apparatus. Interestingly, the level of each protein in these subcellular compartments varies according to their total abundance and between cell types. For example, it was reported that N-Ras and H-Ras maintain the highest Golgi pool (Chiu et al., 2002) (Figure 3). H- and N-Ras traffic between the Golgi and the plasma membrane (PM) depending on their acylation status (Misaki et al., 2010). H-Ras has two palmitoylation sites (Cys residues 181 and 184) and is distributed throughout the Golgi stacks. N-Ras contains one palmitoylation site (Cys residues 181 and 184) and is distributed throughout the Golgi stacks. N-Ras contains one palmitoylation site (C181) and is found mainly at the trans-Golgi (Lynch et al., 2015). H/N-Ras get palmitoylated at the Golgi apparatus by DHHC9 and then transferred to the PM via the secretory pathway (Swarthout et al., 2005). After de-palmitoylation, H/N-Ras traffic back to the Golgi to be re-acylated. Selectively activated RAS at the Golgi by apoptogenic stimuli elicits cell death and prevents cellular transformation (Casar et al., 2018). Treatment with Palmastatin B reportedly blocks the Ras S-palmitoylation cycle, restoring epithelial-like

FIGURE 3 | Golgi associated factors in Epithelial-to-Mesenchymal Transition (EMT). A number of Golgi-localized proteins, including Golgi matrix proteins and enzymes, are linked to changes in Golgi structure and function as cancer cells acquire a mesenchymal-like migratory phenotype.
features and induces dose-dependent cell death in N-Ras mutant melanoma cells (Vujic et al., 2016). Taken together, the Golgi can be regarded as a signaling platform from which proteins like Ras can be activated during EMT.

Golgi positioning and directional cell migration—With relevance to cancer invasion, cell polarity and directional cell migration are highly associated with Golgi positioning and structure. For example, the Golgi ribbon is unlinked and relocated to the side of the nucleus that faces the leading-edge during fibroblast directed cell migration (Pouthas et al., 2008). It is thought that this positioning facilitates polarized transport of proteins such as integrins and lipids, to the growing lamellipodium (Bisel et al., 2008a). In a different study, increased cell migration was associated with a stable placement of the Golgi apparatus rather than its position at the rear or front of the nucleus (Natividad et al., 2018). And alternatively, when cells are forced to migrate along a linear fibronectin pattern, the Golgi is positioned behind the nucleus due to geometrical constraints (Pouthas et al., 2008). Hence, one explanation for the inconclusive position of the Golgi during cell migration may stem from the leading edge spreading further in a typical wounding assay when the substrate is scratched, allowing for the Golgi to preferentially face the leading edge (Millarte and Farhan, 2012). Therefore, it seems that future studies on Golgi positioning during cell migration using traditional methods of scratch assays on 2D substrates, as well as in 3D cell culture models, will provide clarity on this outstanding question.

Repositioning of the Golgi and dynamic alterations of the organelle is carried out by a number of factors including the actin/microtubule network and their associated molecular motors in conjunction with Golgi proteins. Several Golgi proteins are known to regulate cell migration and polarization, including GM130 and GRASPs (Bisel et al., 2008a) (Figure 3). Phosphorylation of GRASP65 results in Golgi unstacking and reorganization at the leading edge of the migrating cell. GRASP65 mutants lacking the phosphorylation site prevented Golgi and centrosome reorientation during cell migration. Similarly, GM130 recruits YSK1 and activates the kinase which phosphorylates downstream cell polarity targets (Preisinger et al., 2004). Inactive YSK1 abrogates Golgi and centrosome reorientation during cell migration. GM130 also interacts with the Rho family GTPase Cdc42, a key regulator of cell polarization (Etienne-Manneville, 2004; Kodani et al., 2008; Baschieri et al., 2014). Loss of GM130 decreased angiogenesis and cancer cell invasion in vitro and suppressed tumorigenesis in a lung cancer mouse model (Chang et al., 2012). Moreover, GM130 expression positively correlated with pathological EMT and invasion of gastric cancer cells through SnaI signaling (Zhao et al., 2015).

However, in a breast and colorectal cancer model, when the authors silenced GM130, it was sufficient to induce E-cadherin downregulation (Baschieri et al., 2014). Moreover, it was demonstrated that depletion of GM130 increased cellular velocity and the invasiveness of breast cancer cells. Conversely, knockdown of cis-Golgi proteins golgin-160 and GMAP210 was reported fragment the Golgi into several mini-stacks and inhibit cell migration (Yadav et al., 2009). Therefore, it seems that the effect of different golgins may be cell-type dependent and perhaps even migration-type dependent (single cell migration as compared to collective cell migration). Although we continue to discover the contributions of different golgins to the cancer cell phenotype, these studies underscore the important roles of golgins in modulating tumorigenesis during EMT and the early steps of the metastatic cascade (Figure 3).

3.2.2 Extracellular Matrix Remodeling

The ECM is comprised of 43 collagen subunits, 36 proteoglycans and ~200 complex glycoproteins – altogether, amounting to roughly 300 macromolecules which constitute the core matrisome (Hynes and Naba, 2012). The extracellular matrix is a dynamic scaffold for cells and serves as mechanical support to maintain tissue integrity and elasticity. But function of the ECM goes beyond this physical platform for cells to reside; due to cell-matrix interactions, signaling cues from cell-surface receptor binding of ECM components modulate key cancer-associated cellular behavior such as proliferation, differentiation, and migration. The Golgi aids in the production of extracellular matrix (ECM) components and activation of key ECM remodeling proteins as tumor cells invade through the basement membrane and migrate through the tumor stroma.

Golgi and enhanced ECM secretion during tumorigenesis—The capacity of the cell to accommodate the enhanced secretion of ECM proteins during tumorigenesis involves a coordinated increase in secretory vesicle biogenesis. Interestingly, Kurie and colleagues recently demonstrated that GRASP55 is part of a Golgin-45/myosinIIA-containing protein complex which activates secretory vesicle biogenesis in the Golgi. In addition, loss of the tumor suppressor gene, p53, up-regulates the expression of the trans-Golgi network localized protein PAQR11, which recruits an adenosine diphosphate ribosylation factor 1-containing protein complex that loads cargos into secretory vesicles (Tan et al., 2021) (Figure 3).

Accordingly, depletion of PAQR11 in human lung adenocarcinoma cells reduced the secretion of proteins - such as the collagen-modifying enzyme procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (PLOD3) – that were enriched in Gene Ontology terms, “ECM degradation,” and “proteolysis regulation”.

ECM remodeling during tumor invasion—In addition to the core matrisome, proteases and other enzymes are also secreted into the extracellular space and participate in the constant remodeling of the ECM to maintain homeostasis of the interstitial matrix and basement membrane. The cycle of ECM remodeling is the balance between deposition of ECM components, and its regulated degradation. Dysregulated ECM composition, stiffness, abundance, and organization contributes to many pathological conditions including cancer. Some of the well-known ECM regulating proteins include collagen crosslinking proteins - like nidogen, lysyl oxidase, and lysyl-hydroxylases, increase matrix stiffness. Conversely, other secreted proteins, such as metalloproteinas and cathepsins, degrade ECM. The main enzymes responsible for ECM degradation are matrix metalloproteinas, such as ADAMs and memprins, which belong to the metzincin enzyme family. There are 23 identified human MMPs that collectively can degrade all ECM...
proteins [see detailed review (Bonnans et al., 2014)]. Often observed upregulated in primary tumors and/or metastases are MMP-1, -2, -3, -7, -9, -13, and -14 (Egeblad and Werb, 2002; Deryugina and Quigley, 2015; Winer et al., 2018). Some other MMPs are also implicated in poor prognoses associated with human cancers.

The role of the Golgi in ECM remodeling during tumor invasion—Interestingly, MMPs1, 2, and 9 secretion was enhanced when a Golgi-localized protein, IMPAD1, was overexpressed in lung adenocarcinoma cells (Bajaj et al., 2020). The authors concluded that IMPAD1 modulates the Golgi-mediated secretion of proteases such as MMPs into the ECM, to promote lung cancer migration and invasion. In addition to secretion, the Golgi also controls two important post-translational modifications (PTMs) of MMPs: glycosylation and proteolytic cleavage. The MMPs exhibit high protein structure homology that can be separated into three domains: the pro-peptide, the catalytic domain, and the haemopexin-like C-terminal domain linked to the catalytic domain by a flexible hinge region. Each domain effectuates a specific activity for the protein and can be modified by highly specific PTMs. Post-translational modifications significantly expand the functionality and fine-tune both enzyme and substrate protein structure, subcellular localization, protein–protein interactions, and degradation [recently reviewed in (Madzharova et al., 2019)].

MMP glycosylation in the Golgi—All MMPs have potential glycosylation sites, with a handful of sites validated with known functions. MMP-9 is a well-characterized glycosylated MMP and is the most extensively glycosylated of all the MMPs (Madzharova et al., 2019). The protease contains 2N-linked glycosylation sites: Asn38 in the pro-domain and Asn120 at the catalytic domain. In addition, the region between the active site and the hemopexin domain is denoted as the OG domain because it contains 14 potential O-Glycosylation sites. The Golgi targeting mechanisms of core 1 β3 galactosyltransferase (C1GalT-1) and core 2N-acetylgalcosaminyltransferase 2/M (C2GnT-2/M), which participate in the early O-glycosylation steps, are carried in vesicular complexes that utilize different golgins for docking to the Golgi: C2GnT-M-VC uses Giantin, while C1GalT1-VC employs the GM130-GRASP65 complex (Petrosyan et al., 2012). Notably, when GalNAc-T1 (GALNT1) is mislocalized from the Golgi to ER, consequential increase in O-glycosylation activates the matrix metalloproteinase MMP14 to promote tumor spread (Nguyen et al., 2017). Based on predictive models and comparison of conserved glycosylation sites near the active site across the MMP family, it is hypothesized that glycosylation of MMPs may serve as an additional layer to diversify the activity of these similarzymogens.

MMP processing in the Golgi—Although most MMPs are secreted into the extracellular space, six members of the MMP family are membrane anchored, also known as membrane-type MMPs (MT-MMPs). MMPs can be grouped into four major groups: gelatinases, matrilysins, archetypal MMPs, and furin-activatable MMPs. All six membrane-type MMPs (MMP-14, -15, -16, -17, -24, and -25) have a furin cleavage site in the pro-peptide, which is a feature also shared by MMP-11 (Pei and Weiss, 1995; Ra and Parks, 2007). Furin is enriched at the Golgi (Figure 3) and cleaves proteins just downstream of a basic amino acid target sequence [canonically, Arg-X-(Arg/Lys) -Arg] (Sato et al., 1996). Interestingly, MMP-14 activation by furin has been shown to depend on GRASPs. Overexpression of GRASPs increased MMP-14 and furin complex formation; the study suggests that GRASPs serves as an adaptor protein coupling MMP-14 with furin since it was shown to interact directly with MMP-14 at the LLY573 motif (Roghi et al., 2010). Hence, not only is Golgi home to important proteases that participate in activation of MMPs, but that GRASPs and other golgins, can moonlight in different functions to ensure proper localization of various enzymes.

Sorting and processing of MMPs and lysosomal enzymes in the Golgi—For many years, the importance of other proteases has been overshadowed by the matrix MMPs in the field of cancer metastasis. However, due to the clinical failure of MMP inhibitors to prevent cancer metastasis, additional proteases such as cathepsins have been investigated as potential candidates for cancer metastasis management. Changes to Golgi structure will impact the fidelity of protein sorting intracellularly and the secretion of proteins to the extracellular space (Xiang et al., 2013). While cathepsins are localized primarily in lysosomes, they can be secreted into the extracellular space where they participate in the degradation of ECM proteins. In this manner, cathepsins are also key regulators of basement membrane structure and their catalytic activity outside of the cell can promote tumor cell invasion and metastasis (Gormley et al., 2011) (Yang et al., 2010). Previous studies have demonstrated the key role of different types of cathepsins in cancer cell invasion, such as cathepsin (CTS) B in glioma (Demchik et al., 1999), CTS-L in ovarian carcinoma (Zhang et al., 2014), and CTS-S in colorectal (Burden et al., 2009) and breast cancer metastasis (Sevenich et al., 2014). Cathepsin D elevation is also a poor prognostic marker for breast, ovarian, prostate, bladder, and melanoma cancer, and has been previously associated with increased risk of relapse and metastasis (Dian et al., 2012; Dian et al., 2014). Breast and prostate cell lines can grow and proliferate more quickly in the presence of secreted pro-cathepsin D (Větvička et al., 1994; Hu et al., 2008). Interestingly, depletion of both GRASPs and GRASPs caused mis-sorting of cathepsin D precursors to the extracellular space (Xiang et al., 2013). Upon characterizing these cells lines lacking GRASP proteins, Wang and colleagues observed significant acceleration of cell cycle progression in GRASP55 and GRASP65 knockdown cells when compared to control cells (Tang et al., 2010; Ahat et al., 2019). Altogether, these studies suggest that the secretion of ECM remodeling proteins depends on the Golgi structure that is required for proper sorting, adequate glycosylation, and cleavage activation of the enzymes.

3.3 Golgi Adaptation During Metastatic Dissemination

3.3.1 Cancer Cell Survival in the Circulation and Attachment to the Endothelium

In the next step of the metastatic cascade, cancer cells disseminate from the primary tumor to establish new
metastases at distant sites mainly through the bloodstream (Figure 2). During hematogenous dissemination, circulating tumor cells encounter normal host cells such as platelets. These interactions can endow tumor cells with the necessary metastatic properties to survive in blood circulation, arrest in vasculature, and establish new tumor growth at the secondary site. In this subsection, we focus on Golgi-localized proteins and their function in cancer cell survival in circulation and attachment to the endothelium.

Alteration of cell adhesion molecules during metastatic dissemination—As mentioned earlier, the Golgi-localized protein PAQR11 has been reported to suppress anoikis, a form of programmed cell death induced upon detachment from extracellular matrix to prevent the re-adhesion of the cell in incorrect locations (Tan et al., 2021). By gaining anoikis-resistance, cancer cells survive in circulation and subsequently colonize ectopic sites where ECM proteins differ from the primary site. One of the ways cancer cells can acquire anoikis-resistance is by changing integrins at the cell surface. There are 18 α subunits and 8 β subunits that have been identified in humans, which are able to generate 24 different αβ heterodimeric integrins (Takada et al., 2007). Since integrins function as heterodimers, the numerous combinations mediate binding preference for specific ligands such as fibronectin, laminin, or collagen—thereby permitting malignant cells to grow in distant organs (Walker et al., 2018). Interestingly, disrupting Golgi structure through GRASP55 depletion reduced the protein expression of α5β1 integrin in cervical cancer and breast cancer cells (Ahat et al., 2019). Other integrins such as αvβ3, α1β1 and α6β1, along with α5β1 are all implicated in cell survival (Avraamides et al., 2008).

It is proposed that integrins also protect circulating cancer cells exposed to shearing forces generated by blood flow in the vasculature. Integrin αvβ3 on tumor cells and αIIbβ3 on activated platelets can bind fibrin to form a platelet-rich thrombus around tumor cells which shields the cells from fluid shear stress (Chen et al., 2015). Additionally, the formation of these platelet-rich thrombi may also mask tumor cells antigens from Natural-Killer (NK) cell immune surveillance. When MHC class I from non-cancerous, normal platelets coating the tumor cells is presented, the malignant cell escapes lysis by the innate immune system (Labelle and Hynes, 2012; Schmied et al., 2021). By surviving the initial steps of hematogenous dissemination, those tumor cells have the chance to stably adhere to endothelial cells and extravasate out of the bloodstream to seed the stroma of new sites.

Golgi alteration and integrin glycosylation during metastatic dissemination—The Golgi is home to glycosyltransferases and glycosidases that cooperate to support glycosylation of nearly half of the human proteome. Glycan modifications are sequentially carried out by these Golgi enzymes that localized to specific Golgi compartments [cis-, medial-, and trans-Golgi cisternae, and the trans-Golgi network (TGN)] according to their function in the biosynthetic pathway. When the Golgi structure is perturbed through knockdown of GRASP proteins, accurate protein glycosylation was impaired (Zhang and Wang, 2016). GRASP depletion, particularly GRASP55 single depletion or GRASP55/65 double depletion, resulted in a decrease in overall glycan quantity, complexity, and glycoprotein composition at the plasma membrane, based on glycomic analysis by mass spectrometry (Xiang et al., 2013). It has been reported that disrupting Golgi structure in cancers results in an increase in sialylation (Schultz et al., 2012). Increased sialylation of carbohydrate determinants such as Sialyl LewisX (sLex) and sialyl-Lewis a (sLea) on cancer cells promote their binding to selectins which may favor their arrest on endothelia. As expected, high expression of sLea and sLea correlated with metastasis and poor survival and by way of contrast, downregulation of these selectin ligands through knockdown of key glycosyltransferases reduced adhesion to selectins and diminished metastatic ability (Schultz et al., 2012). Removal of α2-8 sialic acid residue in the α5 integrin subunit of melanoma cells inhibited cell adhesion to fibronectin (FN), but the opposite was observed for hyposialylation of β1 integrin subunit in myeloid cells which enhanced FN binding. Meanwhile, enrichment of T and sialyl T antigen on β1 integrin enhanced its activity (Liu et al., 2014).

These results demonstrate the differential effects of O-glycosylation on integrins is dependent on the subunit, site, and cell type. In epithelial cells, a shift of N-glycans on integrins to the highly β1, 6 GlcNAc branched type is catalyzed by a resident Golgi enzyme, N-acetylgalactosaminyltransferase V (MGAT5), which leads to decreased cell adhesion and promotes cell motility (Murata et al., 2000) (Granovsky et al., 2000). Conversely, an upregulation of N-acetylgalactosaminyltransferase III (MGAT3) modifies N-glycans with a bisecting GlcNAc residue, suppresses terminal modifications, and reduces integrin-mediated signaling. Through site-directed mutagenesis studies, it was demonstrated that specific N-glycosylation sites on β3 integrin positively regulates αvβ3, but not αvβ1 (Cai et al., 2017). Still, further studies are needed to clarify the structural consequences of individual N-glycan or O-glycan site on integrin activation and to clarify how Golgi unstacking selectively decreases the synthesis of α5β1 integrin.

Other cell adhesion molecules in metastatic dissemination—Although integrins represent a class of proteins found on the plasma membrane for cell adhesion to the ECM, it is equally important to highlight cell-cell contact in the metastatic process which can also be regulated via glycosylation. One example is N-glycosylation of EpCAM, a transmembrane glycoprotein primarily used as an epithelial marker and aberrant expression is associated with cancer. EpCAM belongs to a family of cell adhesion molecules (CAMs) that mediates cell-cell contact; however studies have yet to resolve EpCAM’s role in cell adhesion (Gaber et al., 2018). EpCAM expression is generally lower in squamous cell carcinomas than in adenocarcinomas; while absent in most sarcomas, lymphomas, melanomas, and neurogenic tumors (Went et al., 2004). In contrast, the majority of other cancers express EpCAM at levels much higher than normal non-cancerous controls. At the post-transcriptional level, EpCAM expression can be modulated by N-glycosylation since the protein contains three N-glycosylation sites (Asn74, 111, 198), which have been implicated in protein stability (Munz et al., 2008). A later study confirmed the loss of glycosylation
### TABLE 1 | Golgi enzymes linked to glycosylation alterations in cancer.

| Gene | Golgi protein | Function | Golgi location | Cancer type | Selected References |
|------|---------------|----------|---------------|-------------|---------------------|
| GALNT3 | Polypeptide N-acetylgalactosaminyltransferase 3 | Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor | medial/ trans | pancreatic cancer | Chugh et al. (2016) |
| GALNT2 | Polypeptide N-acetylgalactosaminyltransferase 2 | Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor | medial/ trans | hepatocellular carcinoma | Wu et al. (2011) |
| GALNT6 | Polypeptide N-acetylgalactosaminyltransferase 6 | Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor | medial/ trans | breast cancer, pancreatic cancer, ovarian endometrioid and clear cell carcinoma | Park et al. (2010); Lin et al. (2017) |
| GALNT14 | Polypeptide N-acetylgalactosaminyltransferase 14 | Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor | medial/ trans | breast cancer, pancreatic cancer, non-small-cell lung cancer, and melanoma | Shan et al. (2018) |
| B4GALNT2 | Beta-1,4 N-acetylgalactosaminyltransferase 2 | Transfers a beta-1,4-linked GalNAc to the galactose residue of an alpha-2,3-sialylated chain | trans | colon cancer, breast cancer | Pucci et al. (2020); Yu et al. (2021a) |
| B4GALT3 | Beta-1,4-galactosyltransferase 3 | Responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids | trans | neuroblastoma | Chang et al. (2013) |
| B4GALT1 | Beta-1,4-galactosyltransferase 1 | Responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids | trans | lung cancer, breast cancer, leukemia, colon cancer, hepatocellular cancer, prostate cancer, clear cell renal cell carcinoma, | Wei et al. (2008); Choi et al. (2012); Shinzaki et al. (2012); Zhou et al. (2013); Radhakrishnan et al. (2011); Xie et al. (2016); De Vitis et al. (2019); Kudo et al. (1998); DalfÓlio and Chirico (2001); Lise et al. (2000); Sewell et al. (2006); Marcos et al. (2011); Schultz et al. (2013); Chakraborty et al. (2018); Park and Lee (2013); Dalziel et al. (2001) |
| ST6GAL1 | Beta-galactoside alpha-2,6-sialyltransferase 1 | Transfers sialic acid from CMP-sialic acid to galactose-containing acceptor substrates | trans | stomach cancer, ovarian cancer, colon cancer, colorectal cancer, breast cancer, pancreatic ductal adenocarcinoma, gastric cancer | Kudo et al. (1998); DalfÓlio and Chirico (2001); Lise et al. (2000); Sewell et al. (2006); Marcos et al. (2011); Schultz et al. (2013); Chakraborty et al. (2018); Park and Lee (2013); Dalziel et al. (2001) |
| ST3GAL2 | CMP-N-acetyleneuraminic acid-beta-galactosamine-alpha-2,3-sialyltransferase 2 | A beta-galactoside alpha2-3 sialyltransferase primarily involved in terminal sialylation of ganglio and globo series glycolipids | trans | colorectal cancer | Kudo et al. (1998) |
| ST3GAL3 | CMP-N-acetyleneuraminic acid-beta-1,4-galactoside alpha-2,3-sialyltransferase | Catalyzes the formation of the NeuAc-alpha-2,3-Gal-beta-1,4-GlcNAc- and NeuAc-alpha-2,3-Gal-beta-1,3-GlcNAc- sequences found in terminal carbohydrate groups of glycoproteins and glycolipids | trans | T-cell leukemia | Radhakrishnan et al. (2011) |
| ST3GAL4 | CMP-N-acetyleneuraminic acid-beta-galactosamine-alpha-2,3-sialyltransferase 4 | A beta-galactoside alpha2-3 sialyltransferase involved in terminal sialylation of glycoproteins and glycolipids | trans | colorectal cancer | Kudo et al. (1998) |

(Continued on following page)
| Gene     | Golgi protein                                      | Function                                                                 | Golgi location | Cancer type                              | Selected References                              |
|----------|---------------------------------------------------|--------------------------------------------------------------------------|----------------|------------------------------------------|-------------------------------------------------|
| MGAT5    | Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A | Catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1–6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides C-6 of the core α1-6Man | medial/ trans  | breast cancer, colon cancer              | Seberger and Chaney (1999); Granovsky et al. (2000); Guo et al. (2014) |
| MGAT3    | Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase | Catalyzes the addition of N-acetylglucosamine in beta 1–4 linkage to the beta-linked mannose of the trimannosyl core of N-linked sugar chains, called bisecting N-acetylglucosamine (GlcNAc) | medial       | lung cancer                             | Yoshimura et al. (1995)                          |
| MGAT1    | Catalyzes the first GlcNAc residue to the C-2 of the α1-3Man in the core of Man5GlcNAc2 | Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase | cis/ medial   | prostate cancer, breast cancer, hepatocellular carcinoma, colorectal cancer, pancreatic cancer | Beheshti Zavareh et al. (2012); Yu et al. (2021b); Takayama et al. (2020); Sethi et al. (2014); Zhan et al. (2018) |
| FUT3     | 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase | Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to both the subterminal N-acetyl glucosamine (GlcNAc) of type 1 chain (beta-D-Gal-(1->3)-beta-D-GlcNAc) glycolipids and oligosaccharides via an alpha(1,4) linkage, and the subterminal glucose (Glc) or GlcNAc of type 2 chain (beta-D-Gal-(1->4)-beta-D-GlcNAc) oligosaccharides via an alpha(1,3) linkage, independently of the presence of terminal alpha-L-fucosyl-(1,2) moeetes on the terminal galactose of these acceptors | trans       | gastric carcinoma, lung cancer, breast cancer | Matsuura et al. (1998) |
| FUT6     | 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase | Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to both the subterminal N-acetyl glucosamine (GlcNAc) of a distal alpha2,3 sialylated lactosamine unit of a glycoprotein- or a glycolipid-linked sialoployactosamines chain or of a distal or internal lactosamine unit of a neutral glycoprotein- or a glycolipid-linked poly lactosamines chain through an alpha-1,3 glycosidic linkage | trans       | breast cancer                           | Matsuura et al. (1998) |
| FUT7     | Alpha-(1,3)-fucosyltransferase 7                  | Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to both the subterminal N-acetyl glucosamine (GlcNAc) of a distal alpha2,3 sialylated lactosamine unit of a glycoprotein- or a glycolipid-linked sialoployactosamines chain or of a distal or internal lactosamine unit of a neutral glycoprotein- or a glycolipid-linked poly lactosamines chain through an alpha-1,3 glycosidic linkage | trans       | T cell leukemia                         | Hiraawa et al. (2003) |
| FUT8     | Alpha-(1,6)-fucosyltransferase                    | Catalyzes the addition of fucose in alpha 1–6 linkage to the first GlcNAc residue, next to the peptide chains in N-glycans | medial       | hepatocellular carcinoma, lung cancer, breast cancer | Noda et al. (1998); Wang et al. (2009); Liu et al. (2011); Potapenko et al. (2010) |
| C1GALT1C1| C1GALT1-specific chaperone 1                      | Probable chaperone required for the generation of 1 O-glycan Gal-beta1-3GlcNAc-alpha1-Ser/Thr (T antigen), which is a precursor for many extended O-glycans in glycoproteins. Probably acts as a specific molecular chaperone assisting the folding/ stability of core 1 beta-3-galactosyltransferase (C1GALT1) | cis          | gastric carcinoma, hepatocellular carcinoma | Wang et al. (2010); Ju et al. (2014); Shen et al. (2020) |

(Continued on following page)
TABLE 1: (Continued) Golgi enzymes linked to glycosylation alterations in cancer.

| Gene  | Golgi protein | Function                                                                 | Golgi location | Cancer type          | Selected References            |
|-------|---------------|--------------------------------------------------------------------------|----------------|----------------------|--------------------------------|
| C1GALT1 | Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 | Glycosyltransferase that generates the core 1 O-glycan Gal-beta1-3GalNAc-alpha1-Ser/Thr (T antigen), which is a precursor for many extended O-glycans in glycoproteins | cis            | breast cancer         | Chou et al. (2015)             |
| GCNT3  | Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylgulosaminyltransferase 3 | Glycosyltransferase that can synthesize all known mucin beta 6 N-acetylglicosaminides. Mediates core 2 and core 4 O-glycan branching | medial         | breast cancer, gastric cancer, prostate cancer | Dazieli et al. (2001) |
| GCNT2  | N-acetyllactosaminide beta-1,6-N-acetylgulosaminyltransferase  | Branching enzyme that converts linear into branched poly-N-acetyllactosaminoglycans | medial         | melanoma              | Sweeney et al. (2018)          |

at Asn198 reduced protein stability at the membrane (Chong and Speicher, 2001). Glycosylation sites of many other cell surface proteins part of the glycocalyx have yet to be mapped and characterized in detail, despite cancer literature enumerating a vast number of aberrantly glycosylated substrates [reviewed (Fuster and Esko, 2005; Costa et al., 2020)]. As continued discoveries are made towards understanding the cancer glycome, we expand the possibilities of new therapeutic strategies to exploit glycosylation differences on cell surface glycome, we expand the possibilities of new therapeutic discoveries are made towards understanding the cancer niche (Peinado et al., 2017). Primary tumor cells create a microenvironment lacking cancer cells, but primed for metastatic colonization due to alterations that condition it to support abnormal tumor-growth is termed the pre-metastatic niche (Peinado et al., 2017). The distant microenvironment in secondary sites that is conducive to their survival even before they arrive to establish micrometastasis. These pro-tumorigenic cues are brought about by the numerous tumor-secreted factors and tumor-shed extracellular vesicles. These signaling molecules include various growth factors, cytokines, chemokines, and pro-angiogenic factors of the pro-metastatic secretome. Secreted proteins that have N-terminal signal sequences are conventionally transported from the ER to the Golgi and then to the plasma membrane where they are released to the extracellular space. In contrast, some cytosolic proteins lacking an ER signal sequence bypass the Golgi and are secreted through the unconventional secretion pathway (Grieve and Rabouille, 2011). Although the unconventional pathway does not follow the canonical ER-to-Golgi route, GRASP proteins have been implicated by previous studies in unconventional secretion (Kinseth et al., 2007; Nüchel et al., 2021).

Thus, these findings further implicate the role of Golgi in the adapting cancer cell.

3.3.2 Conventional and Unconventional Secretion and Generation of the Pre-metastatic Niche

The distant microenvironment lacking cancer cells, but primed for metastatic colonization due to alterations that condition it to support abnormal tumor-growth is termed the pre-metastatic niche (Peinado et al., 2017). Primary tumor cells create a microenvironment in secondary sites that is conducive to their survival even before they arrive to establish micrometastasis. These pro-tumorigenic cues are brought about by the numerous tumor-secreted factors and tumor-shed extracellular vesicles. These signaling molecules include various growth factors, cytokines, chemokines, and pro-angiogenic factors of the pro-metastatic secretome. Secreted proteins that have N-terminal signal sequences are conventionally transported from the ER to the Golgi and then to the plasma membrane where they are released to the extracellular space. In contrast, some cytosolic proteins lacking an ER signal sequence bypass the Golgi and are secreted through the unconventional secretion pathway (Grieve and Rabouille, 2011). Although the unconventional pathway does not follow the canonical ER-to-Golgi route, GRASP proteins have been implicated by previous studies in unconventional secretion (Kinseth et al., 2007; Nüchel et al., 2021).

Secretion of pro-metastatic factors—Many tumor-secreted growth factors activate angiogenesis and/or cell activation and differentiation to prepare the pre-metastatic niche. These include vascular endothelial growth factor A (VEGFA), angiopoietin-like 4 (ANGPTL4) and transforming growth factor-α (TGFα). GRASP55 has been shown to interact with the TGFα (Kuo et al., 2000). TGFα is expressed primarily in ectodermic and epithelial cells during normal development and is frequently up-regulated in carcinoma cells (Greten et al., 2001; Awwad et al., 2003; Calvisi and Thorgeirsson, 2005), and expression of TGFα can confer a transformed phenotype and tumorigenesis to normal cells (Derynck, 1990; Lee et al., 1995; Humphreys and Hennighausen, 2000; Shi et al., 2000). Interference with the interaction between GRASP55 and TGFα strongly impairs cell surface expression of TGFα, suggesting an important role for
GRASP55 in TGFα transport and maturation through the Golgi apparatus (Kuo et al., 2000). GRASP55 therefore seems to be a versatile protein that facilitates secretion of growth factors and cytokines supporting the pre-metastatic niche through both the unconventional secretion pathway and conventional secretion pathway.

**GRASP-dependent unconventional secretion**—As described above, some proteins lacking an ER signal sequence can be transported and released by a Golgi-independent but GRASP-dependent unconventional pathway. One such example is interleukin 1 beta (IL-1β) (Zhang et al., 2015). IL-1β has been shown to be upregulated in many solid tumors, including melanoma, colon, lung, breast, or head and neck cancers and is associated with poorer prognosis (Rébé and Ghiringhelli, 2020). IL-1β can modulate gene expression and cytokine production, regulating cellular adhesion and migration, angiogenesis, or immune response. Transforming growth factor-β (TGFβ) and fibroblast growth factor 2 (FGF2) are also released by unconventional secretion. TGFβ-dependent protein synthesis, such as of periostin, plays a key role in the development of the pre-metastatic niche by maintaining future infiltration of metastasis-initiating cells through WNT signaling. Extracellular FGF2 affects proliferation, drug sensitivity, and apoptosis of cancer cells.

### 3.4 Golgi and the Tumor Microenvironment

#### 3.4.1 Golgi Response to Stress

Both primary and secondary tumors are composed of cancer cells and a tumor microenvironment (TME). The tumor microenvironment is comprised of different cell types such as lymphocytes, macrophages, mesenchymal stem cells, adipocytes, endothelial cells, and fibroblasts that are recruited and polarized to a pro-tumor, immunosuppressive phenotype within the tumor microenvironment (Baghban et al., 2020). Non-immune cells also release mitogenic growth factors and pro-angiogenic factors into the TME which further exacerbates the remodeling of the ECM and abnormal vasculature around the tumor. The new vasculature is formed to grant nutrient supply to the tumor; however, as the tumor mass grows, blood supply to the core of the tumor mass is insufficient and the TME becomes hypoxic and nutrient deprived. How does the Golgi respond to cues from the tumor microenvironment?

**Signal transduction and protein homeostasis at the Golgi in cancer cells**—Many signaling molecules are docked on the Golgi membranes and respond to various cellular stressors, leading to the hypothesis that the Golgi operates as a signal hub (Mayinger, 2011). Nutrient deprivation is a common characteristic of the tumor microenvironment (**Figure 4A**); under such stresses, autophagy is a catabolic mechanism that helps cancer cells adapt to metabolic needs during nutrient deprivation, genotoxic stress, growth factor withdrawal and hypoxia. Under glucose starvation and amino acid starvation conditions, a subpopulation of GRASP55 is retargeted from the Golgi to the interface between autophagosomes and lysosomes (**Figure 4B**) to promote autophagosome maturation (Zhang et al., 2018). Interestingly, GRASP55 O-GlcNAcylation is reduced under glucose deprivation causing the protein to relocate to autophagosome-lysosome membranes, demonstrating a link between physiological stress signaling and nutrient sensing by the highly adaptive organelle. Cellular stress such as nutrient deprivation can also activate pro-survival autophagy, which is linked to the loss of Golgi integrity (Núñez-Olvera et al., 2020).
Golgi stress, like ER stress, can cause proteasomal degradation, in attempts to restore Golgi proteostasis. Similar to ERAD (ER-associated degradation), if Golgi stress persists, Golgi-apparatus related degradation (GARD) may be triggered (Figure 4B). GM130 is a degraded locally at the Golgi by cytosolic proteasomes in the presence of Golgi stress, resulting in Golgi dispersal (Eisenberg-Lerner et al., 2020).

Alteration of Golgi pH and glycosylation under stress—Due to shortages in nutrient in the TME, cancer cells undergo a metabolic switch, and favor the fermentation of glucose to lactate, and thus, lowering the pH of the microenvironment (Figure 4A). A normal, healthy Golgi maintains a strict pH gradient across the Golgi stack, where the cis-Golgi has a pH of 6.7 and progressively becomes more acidic at trans-Golgi with a pH of 6.0 (Kellokumpu, 2019). To maintain the distinct pH set points, the Golgi employs ion channels to maintain its homeostasis. Differential expression of ion channels is commonly observed in cancer. Recently NHE7, an NHE family ion channel responsible for the maintenance of cytosolic pH, was shown to regulate luminal acidification of the TGN. Intriguingly, NHE7 deficiency disrupted protein sialylation in pancreatic ductal adenocarcinoma (Galenkamp et al., 2020). Even moderate Golgi pH alterations such as those detected in cancer cells can impair N-glycosylation by inducing selective mislocalization of certain Golgi glycosyltransferases. Of the Golgi glycosyltransferases tested by Kellokumpu and colleagues, alpha(2,3)-sialyltransferase (ST3) was more sensitive to pH changes than alpha(2,6)-sialylation (ST6), beta(1,4)-galactosylation (B4GalT1) or alpha-Mannosidase II (ManII) (Kellokumpu et al., 2002). When the Golgi enzymes are localized to inappropriate compartments, they are less likely to encounter their substrates. Furthermore, since some glycosylation enzymes are known to increase their catalytic function when forming heterodimers, spatial separation of the enzymes into different Golgi and post-Golgi compartments will hinder their oligomerization and functional efficiency. For example, dimerization of ST6 and B4GalT1 permits their full catalytic activity, whereas the absence of this interaction is associated with cancers and hypoxia (Khoder-Agha et al., 2019).

Golgi adaptation to oxidative stress—Within the microenvironment (Figure 4A), oxidative stress may have intrinsic or extrinsic origins. Some stromal components can directly produce reactive oxygen species (ROS), while hypoxia produces oxidant species via dysregulation of the mitochondrial electron transport or of NADPH oxidase activity. A recent study using hydrogen peroxide treatment to study ROS-induced oxidative stress, revealed trans-Golgi membrane tethers are targets of ROS. Golgi degradation of Arl1 and dissociation of GRIP domain-containing proteins Golgin-97 and Golgin-245 from the trans-Golgi was observed when cells were treated with hydrogen peroxide (Ireland S. et al., 2020) (Figure 4B). Hypoxia has also been shown to down- or up-regulate enzymes that synthesize nucleotide sugars in the cytoplasm, Golgi-localized glycosyltransferases, fucosyltransferases, and sialyltransferases (Kellokumpu, 2019). Additionally, activation of the hypoxia inducible factor-1α (HIF-1α)/HEME-OXYGENASE-1 (HO-1) pathway by oxidative stress upregulates the expression of Golgi proteins: GM130, Golgin-97 and mannosidase II (Li et al., 2021). It has been proposed that upregulation of Golgi associated genes during cellular stress serves to increase Golgi function as a compensatory mechanism.

Transcriptional regulation during Golgi stress response—How the Golgi responds to stress and integrates stress signals remains unclear (Figure 4C). While it is known that activation of CREB3 and CREB3L, transcription factors of the Golgi-associated genes ARF4, COPB1, GGA2, and USO1, is increased in metastatic cells (Howley et al., 2018) (Reiling et al., 2013), other Golgi stress response pathways and regulators of these pathways have yet to be described in full mechanistic detail. Currently, six response pathways of the Golgi stress response have been reported in mammalian cells: TFE3, PGSE proteoglycan, MAPK-ETS, mucin, CREB3, and HSP47 pathways (Sasaki and Yoshida, 2019). TFE3 binds a Golgi apparatus stress response element (GASE) in the promoter of Golgi-associated genes, to activate the transcription of some glycosyltransferases (Taniuchi et al., 2015), Golgi structural proteins GCP60, Giantin, and GM130, proteins involved in vesicular transport such as Syntaxin 3A (STX3A), RAB20 (Ras-related protein Rab-20), and Golgi proteases (Oku et al., 2011; Sasaki and Yoshida, 2019). Proteoglycan-type Golgi stress response element (PGSE) is present on the promoters of glycosyltransferases (e.g., B3GAT3, EXT2 and CSGLNACT2), an isomerase (GLCE) and sulfitotransferases (HS6ST1, HSST1, NDST2 and CHST7) (Sasaki et al., 2019). Sensors for each Golgi stress pathway has not been elucidated. The concept of the Golgi stress response is still an active area of research with many outstanding questions. Further understanding of the Golgi stress response (Figure 4) will undoubtedly lead to a more complete view of the role of Golgi in cancer metastasis.

3.4.2 Apoptosis and Golgi

When cellular stress exceeds the compensatory limits of the cell, the apoptotic cascade is ushered in by the activation of caspases. During apoptosis, caspase-mediated cleavage of GRASP65 results in fragmentation of the Golgi (Lane et al., 2002). Specifically, cleavage of GRASP65 (Figure 4C) was shown to promote Fas/CD95-mediated apoptosis via release of C-terminal fragments that act at the mitochondria (Cheng et al., 2010). Other golgins such as Golgin-160 are cleaved by Golgi-localized caspase-2 during apoptosis (Mancini et al., 2000; Maag et al., 2005). GM130, GCC88, p115, Golgin-84, Syntaxin 5, and Giantin are also cleaved into distinct fragments (Figure 4C); some capable of acting as signaling molecules, similar to the aforementioned cleavage fragment of GRASP65 (Lowe et al., 2004). For example, p115 caspase cleavage fragment (Figure 4C) promotes apoptosis through the ERK/p53/PUMA pathway (How and Shields, 2011). During malignant transformation, anti-apoptotic kinases are increased and targeted to the Golgi; often coinciding with Golgi dispersal that is thought to support tumor growth by preventing the arrival of pro-apoptotic signaling kinases to the Golgi (Sundram et al., 2011). The apoptotic activity of PKC-theta regulatory domain is dependent on Golgi localization (Schultz et al., 2003). Conversely, anti-apoptotic proteins can be found at the Golgi, such as
BIRC6 and GAAP (Golgi anti-apoptotic protein). BIRC6 is found at the trans-Golgi where it binds activated caspase 9/ SMAC via its BIR motif and through its UBC domain ubiquitinates the two apoptotic proteins for degradation (Hao et al., 2004). Increasing evidence shows that Golgi is involved in apoptotic signaling. Therefore, mechanisms that promote or inhibit these signals in the Golgi may be worthwhile for researchers to look into given that many anti-cancer treatments result in classical caspase-dependent apoptosis.

4 FUTURE DIRECTION AND CONCLUDING REMARKS

Over 50 years ago, ultrastructural images of the Golgi in cancer cells revealed the hypertrophic morphology of this fascinating, dynamic organelle (Maldonado et al., 1966). Throughout the years, the concept of the Golgi has evolved from being an intermediary station where proteins are trafficked before reaching their final destinations, to being recognized as a signaling hub and responsive component of the endomembrane system that is integral to many cellular functions – such as cell proliferation, cell migration, proteostasis, and apoptosis. Primed to both receive cues from the extracellular environment and to act as the orchestrator of cellular events, the definition of a cancer cell Golgi therefore remains to be refined.

We have only begun to scratch the surface of how the Golgi contributes to cancer metastasis. Golgi function is intimately connected to Golgi structure. Interestingly, both Golgi compaction and Golgi fragmentation have been reported in cancer cells. While most cancer cell lines in culture have an intact Golgi ribbon, future research should investigate the Golgi structure in 3D models that better represent tumor microenvironment and cancer cell progression. Our speculation that Golgi alteration facilitates cancer biogenesis is based on the following reasons: 1) The Golgi undergoes morphological change in tissue culture upon the induction of EMT (Tan et al., 2017) or migration (Bisel et al., 2008b); 2) Golgi fragmentation is often seen in cancer tissues (Maldonado et al., 1966; Tani et al., 1975; Kellokkumpu et al., 2002; Sano et al., 2002; Petrosyan, 2015; Zhang, 2021); 3) Alteration of Golgi functions such as glycosylation is a hallmark of cancer cells (Zhang, 2021). 4) While an organized Golgi structure is required for accurate protein glycosylation and sorting, our study revealed that Golgi fragmentation accelerates protein trafficking and cell proliferation (Xiang et al., 2013; Zhang and Wang, 2016; Bekier et al., 2017). Therefore, although the current literature has not provided solid evidence that Golgi morphological changes contribute to cancer initiation, it is possible that they may facilitate cancer progression.

As new findings emerge, it will be important to address the heterogeneity of cancer phenotypes. Is this heterogeneity due to different stressors eliciting different Golgi responses? How does the Golgi sense these chemical and mechanical changes in the tumor milieu? Do the Golgi architectures vary at different stages of cancer progression, across different cell types, and perhaps even within different regions of the same tumor (e.g., leading edge, necrotic core)? More systematic studies of patient tissues, patient-derived primary cell organoids, 3D culture models, and co-culture systems will help answer these questions. Research on Golgi adaptations to cancer-associated stresses and signaling cues holds great promise for a more conclusive understanding of the link between Golgi and cancer. In addition, with many screening methods now available, such as CRISPR, proximity ligation and inducible degradation, new Golgi functions will be discovered. Furthermore, with innovative approaches such as metabolic glycoengineering (MGE), future studies leveraging the alterations of cancer cellular metabolism to modulate glycosylation at the cell surface, might be useful for studying cancer cells with Golgi glycosyltransferase defects. There is abundant evidence to support Golgi structure alteration and glycosylation defects in cancer, although a solid cause-and-effect relationship between these two factors has not been established yet.

Understanding Golgi structure and function through identifying additional roles of Golgi proteins localized to other compartments of the cell, will pave the way for new avenues to study the relevance of Golgi in cancer metastasis and potentially lead to clinical applications for improving patient outcomes. In sum, the Golgi is an important organelle in cancer biology, and we anticipate Golgi dynamics in malignancies will remain an attractive target for future studies.

AUTHOR CONTRIBUTIONS

SB, DB, and YZ contributed to the conception and design of the review. SB and IM interpreted the relevant literature and assembled figures for this review. All authors revised it critically for important intellectual content and approved the manuscript for publication.

FUNDING

This work was supported by the National Institutes of Health (Grant R35GM130331) and the Fast Forward Protein Folding Disease Initiative of the University of Michigan to YW and by a Lundquist Institute Faculty Grant and award W81XWH2010463 from the Department of Defense to BD.

ACKNOWLEDGMENTS

We thank members of the Wang and Diaz labs for discussions and suggestions on this study. Figures 2–4 were created with BioRender.
REFERENCES

Ahat, E., Xiang, Y., Zhang, X., Bekier, M. E., and Wang, Y. (2019). GRASP Depletion-Mediated Golgi Destruction Decreases Cell Adhesion and Migration via the Reduction of α5β1 Integrin. MBoC 30, 766–777. doi:10.1091/mbc.E18-07-0462

Anglesio, M. S., Evdokimova, V., Melyn, N., Zhang, L., Fernandez, C. V., Grundy, P. E., et al. (2004). Differential Expression of a Novel Ankyrin Containing E3 Ubiquitin-Protein Ligase, Hacel1, in Sporadic Wilms’ Tumor versus normal Kidney. Hum. Mol. Genet. 13, 2061–2074. doi:10.1093/hmg/ddh215

Asada, M., Furukawa, K., Segawa, K., Endo, T., and Kobata, A. (1997). Increased Expression of Highly Branched N-Glycans at Cell Surface Is Correlated with the Malignant Phenotypes of Mouse Tumor Cells. Cancer Res. 57, 1073–1080.

Avraamides, C. J., Garmny-Susini, B., and Varner, J. A. (2008). Integrins in Depletion-Mediated Golgi Destruction Decreases Cell Adhesion and Migration. Cancer Res. 68, 4364–4371.

Bai, X., Thinn, A. M. M., Wang, Z., Shan, H., and Zhu, J. (2017). The Importance of N-Glycosylation on β3 Integrin Ligand Binding and Conformational Regulation. Sci. Rep. 7, 4656. doi:10.1038/s41598-017-04844-w

Capaci, V., Bascetta, L., Fantuz, M., Beznoussenko, G. V., Sommaggio, R., Cincilla, V., et al. (2020). Mutant P53 Induces Golgi Tubulo-Vesiculation Driving a Prometastatic Secretome. Nat. Commun. 11, 1–19. doi:10.1038/s41467-020-17596-5

Casar, B., Badrock, A. P., Jiménez, I., Arozarena, L., Colón-Bolea, P., Lorenzo-Martin, L. F., et al. (2018). RAS at the Golgi Antagonizes Malignant Transformation through PTPrx-Mediated Inhibition of ERK Activation. Nat. Commun. 9, 1–17. doi:10.1038/s41467-018-05941-8

Castejón, O. (1999). Ultrastructural Pathology of Golgi Apparatus of Nerve Cells in Human Brain Edema Associated to Brain Congenital Malformations, Tumours and Trauma. J. submicrosc. Cytol. Pathol. 31, 203–213.

Chakraborty, A., Dorsett, K. A., Trumnell, H. Q., Yang, E. S., Oliver, P. G., Bonner, J. A., et al. (2018). ST6GAl1 Sialytransferase Promotes Chemoresistance in Pancreatic Ductal Adenocarcinoma by Abrogating Gemcitabine-Mediated DNA Damage. J. Biol. Chem. 293, 984–994. doi:10.1074/jbc.M117.805884

Chang, H.-H., Chen, C.-H., Chou, C.-H., Liao, Y.-F., Huang, M.-J., Chen, Y.-H., et al. (2013). β-1,4-Galactosyltransferase III Enhances Invasive Phenotypes via β1-Integrin and Predicts Poor Prognosis in Neuroblastoma. Clin. Cancer Res. 19, 1703–1716. doi:10.1158/1078-0432.CCR-12-2367

Chang, S.-H., Hong, S.-H., Jiang, H.-L., Minai-Tehrani, A., Yu, K.-N., Lee, J.-H., et al. (2012). GolgiGM2/GM3, Cis-Golgi Matrix Protein, Is a Novel Target of Anticancer Gene Therapy. Mol. Ther. 20, 2052–2063. doi:10.1038/mt.2012.125

Chen, J., Green, J., Yurdagul, F., Albert, P., Mclnnis, M. C., and O’R, A. W. (2015). αvβ3 Integrins Mediate Flow-Induced NF-κB Activation, Promflammatory Gene Expression, and Early Atherogenic Inflammation. Am. J. Pathol. 185, 2578–2589. doi:10.1016/j.ajpath.2015.05.013

Cheng, J. P. X., Betin, V. M. S., Weir, H., Shelnman, G. M. A., Moss, D. K., and Lane, J. D. (2010). Caspase Cleavage of the Golgi Stacking Factor GRASP65 Is Required for Fas/CD95-Mediated Apoptosis. Cell Death Dis. 1, e82. doi:10.1038/cddis.2010.59

Cheng, K. W., Lahad, J. P., Kuo, W.-L., Lapuk, A., Yamada, K., Auersperg, N., et al. (2004). The RARB2 Small GTPase Determines Aggressiveness of Ovarian and Breast Cancers. Nat. Med. 10, 1251–1256. doi:10.1038/nm1125

Chia, J., Tham, K. M., Gill, D. J., Bard-Chapeau, E. A., and Bard, F. A. (2014). ERK8 Is a Negative Regulator of O-GalNAc Glycosylation and Cell Migration. eLife 3, e10818. doi:10.7554/eLife.01828

Ching, Y.-P., Leong, V. Y. L., Lee, M.-F., Xu, H.-T., Jin, D.-Y., and Ng, I. O.-L. (2007). P21-activated Protein Kinase Is Overexpressed in Hepatocellular Carcinoma and Enhances Cancer Metastasis Involving C-Jun NH2-terminal Kinase Activation and Paxillin Phosphorylation. Cancer Res. 67, 3601–3608. doi:10.1158/0008-5472.CAN-06-3994

Chiu, V. K., Bivona, T., Hach, A., Saouss, J. B., Silletti, J., Wiener, H., et al. (2002). R-Ras Signaling on the Endoplasmic Reticulum and the Golgi. Nat. Cell Biol. 4, 343–350. doi:10.1038/ncb783

Choi, H.-J., Chung, T.-W., Kim, C.-H., Jeong, H.-S., Joo, M., Youn, B., et al. (2012). Nanoparticles: Implications in Cancer Therapy and Diagnosis. J. Biomed. Bioph. Sci. 2, 5813. doi:10.1074/jbc.M008839200

Chou, C. H., Huang, M. J., Chen, C.-H., Shyu, M.-K., Huang, J., Hung, J.-S., et al. (2015). Up-regulation of GIGALT1 promotes breast cancer cell growth through MUC1-C signaling pathway. Oncotarget 6, 6123–6135.

Chugh, S., Meza, J., Sheinin, Y. M., Ponnusamy, M. P., and Batra, S. K. (2016). Loss of N-Acetylgalactosaminyltransferase 3 in Poorly Differentiated Pancreatic Cancer: Augmented Aggressiveness and Aberrant ErbB Family Glycosylation. Br. J. Cancer 114, 1376–1386. doi:10.1038/bjc.2016.116

Costa, A. F., Campos, D., Reis, C. A., and Gomes, C. (2020). Targeting αvβ3 Integrin Ligand Binding and Conformational Changes: A New Road for Cancer Drug Discovery. Glycoconjugate J. 15, 6042–6051. doi:10.1007/s10719-020-09320-0

Cumin, C., Huang, Y.-L., Everest-Dass, A., and Jacob, F. (2021). Deciphering the Role of a Newly Discovered, Highly Enriched αvβ3 Integrin on Pancreatic Cancer Metastasis. Cell Commun Signal 19, 7579–7594. doi:10.1186/s12951-020-00842-5
Khoder-Agha, F., Harrus, D., Brysbaert, G., Lensink, M. F., Harduin-Lepers, A., Glumoff, T., et al. (2019). Assembly of BAG3L1/STAG3L1 Heteromers in the Golgi Membranes Involves Lateral Interactions via Highly Charged Surface Domains. J. Biol. Chem. 294, 14383–14393. doi:10.1074/jbc.RA119.099339

Kienzle, C., Eister, S. A., Villeneuve, J., Brummer, T., Olayioye, M. A., and Hausser, A. (2013). PKD Controls Mitotic Golgi Complex Fragmentation through a Raf-MEK1 Pathway. Mol. Biol. Cell. 24, 222–233. doi:10.1091/mbc.E12-03-0198

Kinnest, M. A., Anjard, C., Fuller, D., Guizzunti, G., Loomis, W. F., and Malhotra, V. (2007). The Golgi-Associated Protein GRASP Is Required for Unconventional Protein Secretion during Development. Cell 130, 524–534. doi:10.1016/j.cell.2007.06.029

Kodani, A., Kristensen, I., Huang, L., Sütterlin, C., and Glick, B. S. (2008). GM130-Dependent Control of Cdc42 Activity at the Golgi Regulates Centrosome Organization. Mol. Biol. Cell 20 (4), 1192–1200. doi:10.1091/mbc.e08-08-0834

Kuo, A., Zhong, L., Lane, W. S., and Derynck, R. (2000). Transmembrane Transforming Growth Factor-Alpha Tethers to the PDZ Domain-Containing, Golgi Membrane-Associated Protein p59/GRASP55. Embryonic J. 19, 6427–6439. doi:10.1093/embob/19.23.6427

Kudo, T., Ikehara, Y., Morozumi, K., Watanabe, M., Nakamura, M., et al. (1998). Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Lab. Invest. J. Tech. Med. Pathol. 78, 797–811.

Labelle, M., and Hynes, R. O. (2012). The Initial Hours of Metastasis: the Transforming Growth Factor-Alpha Tethers to the PDZ Domain-Containing, Golgi Membrane-Associated Protein p59/GRASP55. Mol. Biol. Cell. 23, 2224, 14383

Lin, T.-C., Chen, S.-T., Huang, M.-C., Huang, J., Hsu, C.-L., Juan, H.-F., et al. (2020). O-Glycosylation and Activity. PloS one 15, e0234237. doi:10.1371/journal.pone.0234237

Lin, C.-Y., Madsen, M. L., Yarm, F. R., Jang, Y.-J., Liu, X., and Erikson, R. L. (2000). The Golgi Architecture and Cell Sensing. Biochem. Soc. Trans. 26, 1063–1072. doi:10.1042/BST20180323

Marchat, L. A., Puente-Rivera, J., et al. (2020). A Novel Protective Role for microRNA-3135b in Golgi Apparatus Fragmentation in Breast Cancer Cells. Cancer Discov. 10, 1099. doi:10.1158/2326-7482.CD-19-1566. Part III.23

Marchat, L. A., Puente-Rivera, J., et al. (2020). A Novel Protective Role for microRNA-3135b in Golgi Apparatus Fragmentation in Breast Cancer Cells. Cancer Discov. 10, 1099. doi:10.1158/2326-7482.CD-19-1566. Part III.23

Maldonado, J., Brown, A., Bayrd, E., and Pease, G. (1966). Ultrastructure of the Fucosylated Tubule System of DU145 Prostate Cancer Cells Is Derived from a Partially Fragmented Golgi Complex and its Formation Is Actin-Dependent. J. Cell Biol. 19, 281–294. doi:10.1083/jcb.19.1.281

Malmqvist, M., Fellinger, K., Hofmann, T., Schmitt, B., and Gires, O. (2008). The Alpha-1,2 Fucosylation Drives MMP14 Activation, Tumor Growth, and Metastasis. J. Biol. Chem. 283, 20175–20184. doi:10.1074/jbc.M802184200

Munz, M., Belluco, C., Perera, S. P., Patel, R., Thomas, P., and Ganguly, A. (2000). Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients. Hybridoma 19, 281–286. doi:10.1089/02724500429828

Núñez-Olvera, S. I., Chávez-Munguía, B., del Rocío Terrones-Gurrola, M. C., et al. (2018). The Differential Palmitoylation States of N-Ras and H-Ras Determine Their Distinct Golgi Subcompartment Localizations. J. Cel. Physiol. 230, 610–619. doi:10.1002/jcp.2779

Nguyen, A. T., Chia, J., Ros, M., Hui, K. M., Salël, F., and Bard, F. (2017). Organellar Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis. Cancer cell 32, 659–663. doi:10.1016/j.ccell.2017.10.001

Noda, K., Miyoshi, E., Uozumi, N., Yamagami, S., Ikeda, Y., Gao, C.-X., et al. (1998). Gene Expression of α-1 Fucosyltransferase in Human Hepatoma Tissues: A Possible Implication for Increased Fucosylation of Y- fetoprotein. Hepatology, 28, 944–952. doi:10.1002/hep.107280408

Nolli, D., Capone, A., Rosati, F., and Della Giovinappa, C. (2020). The Alpha-1,2 Fucosylated Tubule System of DU145 Prostate Cancer Cells Is Derived from a Partially Fragmented Golgi Complex and its Formation Is Actin-Dependent. Exp. Cel. Res. 396, 112324. doi:10.1016/j.yexcr.2020.112324

Nüñez-Olvera, S. I., Chávez-Munguía, B., del Rocío Terrones-Gurrola, M. C., Marchat, L. A., Puente-Rivera, J., Ruiz-García, E., et al. (2020). A Novel Protective Role for microRNA-3135b in Golgi Apparatus Fragmentation Induced by Chemotherapy via GOLPH3/AKT1/mTOR axis in Colorectal Cancer Cells. Sci. Rep. 10, 10555. doi:10.1038/s41598-020-67550-0
in β-1,4-Galactosyltransferase. Gastroenterology 142, 1172–1182. doi:10.1053/j.gastro.2012.02.008

Shorter, J., Watson, R., Giannakou, M. E., Clarke, M., Warren, G., and Barr, F. A. (1999). GRASP55, a Second Mammalian GRASP Protein Involved in the Stacking of Golgi Cisternae in a Cell-Free System. EMBO J. 18, 4949–4960. doi:10.1093/emboj/18.18.4949

Sundram, V., Chauhan, S. C., and Jaggi, M. (2011). Emerging Roles of Protein Kinase D1 in Cancer. Mol. Cell Res. 9, 985–996. doi:10.1016/j.mciro.2011.02.021

Swarthout, J. T., Lobo, S., Farh, L., Croke, M. R., Greenstreet, W. K., Deschenes, R. J., et al. (2005). DHHCH9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras*. J. Biol. Chem. 280, 31141–31148. doi:10.1074/jbc.m50413200

Sweeney, J., Liang, J., Antonopoulous, A., Giovannone, N., Kang, S., Mondala, T. S., et al. (2018). Loss of GCNT2/B1-Branched Glycans Enhances Melanoma Growth and Survival. Nat. Commun. 9, 3368. doi:10.1038/s41467-018-05795-0

Takada, Y., Ye, X., and Simon, S. (2007). The Integmins. Genome Biol. 8, 215. doi:10.1186/gb-2007-8-5-215

Taniguchi, M., Nadanaka, S., Tanakura, S., Sawaguchi, S., Midori, S., Kawai, Y., et al. (1975). Fenestrae Stacking of Golgi Cisternae in a Cell-Free System. J. Struct. Funct. Mol. Biol. 31141–31148. doi:10.1016/0074-9869(75)90251-8

Vujic, I., Sanlorenzo, M., Esteve-Puig, R., Vujic, M., Kwong, A., Tsumura, A., et al. (2016). Acyl Protein Thioesterase 1 and 2 (APT-1, APT-2) Inhibitors Palmostatin B, ML348 and ML349 Have Different Effects on NRAS Mutant Melanoma Cells. Oncotarget 7, 7297–7306. doi:10.18632/oncotarget.6907

Walker, C., Mojares, E., and del Río Hernández, A. (2018). Role of Extracellular Matrix in Development and Cancer Progression. Jims 19, 3028. doi:10.2390/jims-2018-0190

Wang, M., Long, R., Comunale, M., Junaidi, O., Marrero, J., Di Biscaglia, A., et al. (2009). Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma. Cancer Epidemiol. biomarkers Prev. 18, 1914–1921. doi:10.1158/1055-9965.epi-08-0980

Wang, Y., Ju, T., Ding, X., Xia, B., Wang, W., Xia, L., et al. (2010). Cosme Is an Essential Chaperone for Correct Protein O-Glycosylation. Proc. Natl. Acad. Sci. 107, 9228–9233. doi:10.2390/embr.2008-0365

Weiner, A., Adams, S., and Mignatti, P. (2018). Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures into Future Successes. Mol. Cancer Ther. 17, 1147–1155. doi:10.1158/1535-7163.MCT-17-0646

Wu, J., and Akhmanova, A. (2017). Microtubule-Organizing Center. Annu. Rev. Cell Dev. Biol. 33, 51–75. doi:10.1146/annurev-cellbio-100616-000615

Yang, Y., Liu, D., Zhou, F., Ge, Y., Xu, J., Yun, X., et al. (2008). Identification of β-1,4-Galactosyltransferase I as a Target Gene of Hbx-Induced Cell Cycle Progression of Hepatoma Cell. J. Hepatol. 49, 1029–1037. doi:10.1016/j.jhep.2008.09.003

Weller, S. G., Capitaní, M., Cao, H., Micaroni, M., Luini, A., Sallese, M., et al. (2010). Src Kinase Regulates the Integrity and Function of the Golgi Apparatus via Activation of Dynamin 2. Proc. Natl. Acad. Sci. USA 107, 5863–5868. doi:10.1073/pnas.0915231107

Wen, P. T. H., Lugli, A., Meier, S., Bundi, M., Mirlicher, S., Gauer, T., et al. (2004). Frequent EpCam Protein Expression in Human Carcinomas. Hum. Pathol. 35, 122–128. doi:10.1016/j.humpath.2003.08.026

Winer, A., Adams, S., and Mignatti, P. (2018). Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures into Future Successes. Mol. Cancer Ther. 17, 1147–1155. doi:10.1158/1535-7163.MCT-17-0646

Xie, H., Zhu, Y., An, H., Wang, H., Zhu, Y., Fu, H., et al. (2016). Increased BGALT1 Expression Associates with Adverse Outcome in Patients with Non-metastatic clear Cell Renal Cell Carcinoma. Oncotarget 7, 32723–32730. doi:10.18632/oncotarget.8737

Yadav, S., Puri, S., and Linstedt, A. D. (2009). A Primary Role for Golgi Positioning in Directed Secretion, Cell Polarity, and Wound Healing. Mol. Biol. Cell. 20, 1728–1736. doi:10.1091/mbc.e08-10-1077

Yang, Y., Antin, P., Berx, G., Blaupain, C., Brubletz, T., Bronner, M., et al. (2020). Guidelines and Definitions for Research on Epithelial-Mesenchymal Transition. Nat. Rev. Mol. Cell Biol. 21, 341–352. doi:10.1038/s41580-2020-0237-9

Yang, Y., Lim, S., Choong, L., Lee, H., Chen, Y., Chong, P., et al. (2010). Cathepsin S Mediates Gastric Cancer Cell Migration and Invasion via a Putative Network of Metastasis-Associated Proteins. J. Proteome Res. 9, 4767–4778. doi:10.1021/pr100492x

Yin, Y. X., Shen, F., Pei, H., Ding, Y., Zhao, H., Zhao, M., et al. (2012). Increased Expression of Rab25 in Breast Cancer Correlates with Lympmatic Metastasis. Tumor Biol. 33, 1581–1587. doi:10.1007/s13277-012-0412-5

Yoshimura, M., Ibara, Y., Matsuzawa, Y., and Taniguchi, N. (1996). Aberrant Glycosylation of E-Cadherin Enhances Cell-Cell Binding to Suppress Metastasis. J. Biol. Chem. 271, 13811–13815. doi:10.7429/bc.1996.13811

Yoshimura, M., Nishikawa, A., Ibara, Y., Taniguchi, S., and Taniguchi, N. (1995). Suppression of Lung Metastasis of B16 Mouse Melanoma by N-Acetylgalactosaminyltransferase III Gene Transfection. Proc. Natl. Acad. Sci. U. S. A. 92, 8754–8758. doi:10.2390/embr.2008.004222

Yu, P., Zhu, L., Cui, K., Du, Y., Zhang, C., Ma, W., et al. (2021a). B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting with HLA-B Protein. Front. Oncol. 11, 722828. doi:10.3389/fonc.2021.722828

Yu, R., Longo, J., van Leeuwen, J. E., Zhang, C., Branchard, E., Elbaz, M., et al. (2021b). Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced N-Glycosylation Abundance and Branching. Cancer Res. 81, 2625–2635. doi:10.1158/0008-5472.CAN-20-2642
Zhan, L., Chen, L., and Chen, Z. (2018). Knockdown of FUT3 Disrupts the Proliferation, Migration, Tumorigenesis and TGF-β Induced EMT in Pancreatic Cancer Cells. Oncol. Lett. 16, 924–930. doi:10.3892/ol.2018.8738
Zhang, M., Kenny, S. J., Ge, L., Xu, K., and Schekman, R. (2015). Translocation of Interleukin-1β into a Vesicle Intermediate in Autophagy-Mediated Secretion. eLife 4, e11205. doi:10.7554/eLife.11205
Zhang, W., Wang, S., Wang, Q., Yang, Z., Pan, Z., and Li, L. (2014). Overexpression of Cysteine Cathepsin L Is a Marker of Invasion and Metastasis in Ovarian Cancer. Oncol. Rep. 31, 1334–1342. doi:10.3892/or.2014.2967
Zhang, X. (2021). Alterations of Golgi Structural Proteins and Glycosylation Defects in Cancer. Front. Cel Dev. Biol. 9, 665289. doi:10.3389/fcell.2021.665289
Zhang, X., Wang, L., Ireland, S. C., Ahat, E., Li, J., Bekier, M. E., et al. (2019). GORASP2/GRASP55 Collaborates with the PtdIns3K UVRAG Complex to Facilitate Autophagosome-Lysosome Fusion. Autophagy 15, 1787–1800. doi:10.1080/15548627.2019.1596480
Zhang, X., Wang, L., Lak, B., Li, J., Jokitalo, E., and Wang, Y. (2018). GRASP55 Senses Glucose Deprivation through O-GlcNAcylation to Promote Autophagosome-Lysosome Fusion. Develop. Cel 45, 245–261. e246. doi:10.1016/j.develcel.2018.03.023
Zhang, X., and Wang, Y. (2016). Glycosylation Quality Control by the Golgi Structure. J. Mol. Biol. 428, 3183–3193. doi:10.1016/j.jmb.2016.02.030
Zhao, J., Yang, C., Guo, S., and Wu, Y. (2015). GM130 Regulates Epithelial-To-Mesenchymal Transition and Invasion of Gastric Cancer Cells via Snail. Int. J. Clin. Exp. Pathol. 8, 10784–10791.

Zhou, H., Ma, H., Wei, W., Ji, D., Song, X., Sun, J., et al. (2013). B4GALT Family Mediates the Multidrug Resistance of Human Leukemia Cells by Regulating the Hedgehog Pathway and the Expression of P-Glycoprotein and Multidrug Resistance-Associated Protein 1. Cell Death Dis 4, e654. doi:10.1038/cddis.2013.186

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Bui, Mejia, Díaz and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.